Physician profile
Dmitriy Grinshpun
NPI 1265445639
$84,428.16
in general payments reported to CMS, 2019-2025
57 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $14K · 2021: $10K · 2022: $12K · 2023: $14K · 2024: $9,724 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $16K · Education: $17.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,625.00 |
| Food and Beverage | $15,816.88 |
| Education | $17.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $38,526.56 | 2021-2025 | |
| Allergan, INC. | $13,050.40 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $9,979.31 | 2019-2022 | |
| Ucb, INC. | $2,215.47 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Sk Life Science, INC. | $2,108.12 | 2020-2025 | Xcopri |
| Amneal Pharmaceuticals LLC | $1,511.05 | 2019-2025 | Rytary, Crexont, Ongentys |
| Biogen, INC. | $1,462.34 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Neurocrine Biosciences, INC. | $1,410.75 | 2020-2025 | Ingrezza, Ongentys |
| Otsuka America Pharmaceutical, INC. | $1,194.57 | 2022-2025 | Rexulti, Nuedexta |
| Eisai INC. | $979.38 | 2019-2024 | |
| Axsome Therapeutics, INC. | $909.69 | 2023-2025 | Auvelity, Symbravo |
| Lundbeck LLC | $837.84 | 2019-2025 | Vyepti, Rexulti |
| Acadia Pharmaceuticals INC | $770.56 | 2019-2025 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $756.88 | 2019-2025 | |
| Mdd US Operations, LLC | $743.17 | 2021-2025 | Gocovri, Gocovri |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitriy Grinshpun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.